Evidence map›Paper›PMID 33233566›Full record

ArticleCancers2020

Effect of High-Dose vs Standard-Dose Vitamin D

Justin C Brown, Michael H Rosenthal, Chao Ma, Sui Zhang, Halla S Nimeiri, Nadine J McCleary, Thomas A Abrams, Matthew B Yurgelun, James M Cleary, Douglas A Rubinson and 18 more

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 2 pooled it
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 2 syntheses or guidelines pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors at 14 institutions in 1 country.

Justin C BrownPennington Biomedical Research Center, Baton Rouge, LA 70808, USA.ORCID 0000-0001-7540-4913
Michael H RosenthalDana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA.ORCID 0000-0002-5085-3904
Chao MaDana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA.
Sui ZhangDana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA.
Halla S NimeiriDivision of Hematology Oncology, Department of Medicine, Northwestern University, Chicago, IL 60611, USA.
Nadine J McClearyDana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA.
Thomas A AbramsDana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA.ORCID 0000-0003-3101-1573
Matthew B YurgelunDana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA.
James M ClearyDana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA.
Douglas A RubinsonDana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA.ORCID 0000-0002-5337-5231
Deborah SchragDana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA.
Andrea J BullockBeth Israel Deaconess Medical Center, Boston, MA 02215, USA.
Jill AllenMassachusetts General Hospital, Boston, MA 02114, USA.
Dan ZuckermanSt Luke's Mountain States Tumor Institute, Boise, ID 83712, USA.
Emily ChanVanderbilt University Medical Center, Nashville, TN 37232, USA.
Jennifer A ChanDana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA.
Brian WolpinDana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA.
Michael ConstantineDana-Farber at Milford Regional Medical Center, Milford, MA 01757, USA.
Douglas J WecksteinNew Hampshire Oncology Hematology, Hookset, NH 03106, USA.
Meredith A FaggenDana-Farber at South Shore Hospital, South Weymouth, MA 02190, USA.
Christian A ThomasNew England Cancer Specialists, Scarborough, ME 04074, USA.ORCID 0000-0001-7154-5305
Chryssanthi KourniotiNewton-Wellesley Hospital, Newton, MA 02462, USA.
Chen YuanDana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA.
Hui ZhengMassachusetts General Hospital, Boston, MA 02114, USA.
Bruce W HollisDepartment of Pediatrics, Department of Medicine, Medical University of South Carolina, Charleston, SC 29425, USA.
Charles S FuchsYale Cancer Center, New Haven, CT 06510, USA.
Kimmie NgDana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA.ORCID 0000-0003-0631-1494
Jeffrey A MeyerhardtDana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA.
Harvard University · USMassachusetts General Hospital · USBeth Israel Deaconess Medical Center · USMedical University of South Carolina · USNew England Cancer Specialists · USNew Hampshire Hospital · USNewton Wellesley Hospital · USNorthwestern University · USPennington Biomedical Research Center · USRegional Medical Center · USSouth Shore Hospital · USSt. Luke's Mountain States Tumor Institute · USVanderbilt University Medical Center · USYale Cancer Center · US

Funding

Tracking & Evaluation CoreU54GM104940 · NIGMS · LSU PENNINGTON BIOMEDICAL RESEARCH CTR · PI JUDD E SHELLITO · 2012 to 2026
$69.1M
Tissue and Pathology ResourcesP50CA127003 · NCI · DANA-FARBER CANCER INST · PI BASS, ADAM JOEL · 2007 to 2023
$33.2M
Research BaseP30DK072476 · NIDDK · LSU PENNINGTON BIOMEDICAL RESEARCH CTR · PI Sujoy Ghosh · 2005 to 2026
$26.5M
Novel randomized controlled trials of vitamin D supplementation in patients with colorectal cancer: Impact on survival and biologyR01CA205406 · NCI · DANA-FARBER CANCER INST · PI Kimmie Ng · 2017 to 2026
$4.9M
Dietary And Lifestyle Determinants Of Colon Cancer Recurrence and SurvivalR01CA118553 · NCI · YALE UNIVERSITY · PI FUCHS, CHARLES S · 2007 to 2019
$4.4M
Impact of Celecoxib and Inflammation on Survival in Stage III Colon CancerR01CA169141 · NCI · YALE UNIVERSITY · PI FUCHS, CHARLES S · 2013 to 2018
$3.9M
Transdisciplinary Research in Energetics and Cancer (TREC) Training GrantR25CA203650 · NCI · YALE UNIVERSITY · PI IRWIN, MELINDA L · 2016 to 2025
$2.9M
Inflammation, Physical Activity, and Colon Cancer Recurrence and SurvivalR00CA218603 · NCI · LSU PENNINGTON BIOMEDICAL RESEARCH CTR · PI BROWN, JUSTIN C · 2019 to 2021
$747k
National Institute of General Medicine Sciences U54-GM104940NCI NIH HHS P50CA127003NCI NIH HHS R00 CA218603NCI NIH HHS R00-CA218603NCI NIH HHS R01 CA118553NCI NIH HHS R01CA118553NCI NIH HHS R01 CA169141NCI NIH HHS R01 CA205406NCI NIH HHS R01CA205406NCI NIH HHS R25-CA203650NIDDK NIH HHS P30 DK072476NIDDK NIH HHS P30-DK072476NIGMS NIH HHS U54 GM104940
6 · The paper itself

Abstract

Skeletal muscle and adipose tissue express the vitamin D receptor and may be a mechanism through which vitamin D supplementation slows cancer progression and reduces cancer death. In this exploratory analysis of a double-blind, multicenter, randomized phase II clinical trial, 105 patients with advanced or metastatic colorectal cancer who were receiving chemotherapy were randomized to either high-dose vitamin D

Indexed as

adipose tissuecholecalciferolcolorectal neoplasmsmediationprognosisrandomizedskeletal muscle

Identifiers

PMID33233566
PMCPMC7699725
OpenAlexW3099142353

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.